Rallybio Corp
RLYB0.556USD
+0.021+3.87%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
23.12MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Rallybio Corp Unternehmen
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
Unternehmensinformationen
BörsenkürzelRLYB
Name des UnternehmensRallybio Corp
IPO-datumJul 29, 2021
CEODr. Stephen (Steve) Uden, M.D.
Anzahl der mitarbeiter25
WertpapierartOrdinary Share
GeschäftsjahresendeJul 29
Addresse234 Church Street
StadtNEW HAVEN
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl06510
Telefon12038593820
Websitehttps://rallybio.com/
BörsenkürzelRLYB
IPO-datumJul 29, 2021
CEODr. Stephen (Steve) Uden, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.36K
+1.56%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
23.88K
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.24K
+184.74%
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Wendy K. Chung, M.D., Ph.D.
Dr. Wendy K. Chung, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
--
--
Dr. Hui Liu, Ph.D.
Dr. Hui Liu, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lucian Iancovici, M.D.
Dr. Lucian Iancovici, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.36K
+1.56%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
23.88K
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.24K
+184.74%
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
FY2024
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
636.00K
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 2
Aktualisiert: Wed, Jul 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Viking Global Investors LP
10.08%
Johnson & Johnson Innovation-JJDC, Inc.
8.74%
5AM Ventures
8.72%
New Leaf Venture Partners LLC
7.93%
TPG Capital, L.P.
7.28%
Other
57.25%
Aktionäre
Aktionäre
Anteil
Viking Global Investors LP
10.08%
Johnson & Johnson Innovation-JJDC, Inc.
8.74%
5AM Ventures
8.72%
New Leaf Venture Partners LLC
7.93%
TPG Capital, L.P.
7.28%
Other
57.25%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
35.25%
Investment Advisor/Hedge Fund
15.11%
Investment Advisor
13.40%
Private Equity
7.28%
Individual Investor
4.16%
Hedge Fund
3.84%
Research Firm
0.25%
Pension Fund
0.03%
Other
20.68%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
146
33.40M
80.26%
-5.22M
2025Q1
153
34.13M
82.02%
-4.90M
2024Q4
156
33.77M
81.40%
-4.07M
2024Q3
163
33.31M
80.30%
-4.27M
2024Q2
165
34.52M
83.29%
-5.35M
2024Q1
149
33.11M
86.93%
-2.72M
2023Q4
143
34.47M
90.96%
-619.59K
2023Q3
138
35.89M
94.72%
-1.76M
2023Q2
134
36.21M
95.77%
-44.55K
2023Q1
130
35.24M
93.30%
-1.12M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Viking Global Investors LP
4.19M
10.08%
--
--
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
3.64M
8.74%
--
--
Mar 31, 2025
5AM Ventures
3.63M
8.72%
--
--
Mar 31, 2025
New Leaf Venture Partners LLC
3.30M
7.93%
--
--
Mar 31, 2025
TPG Capital, L.P.
3.03M
7.28%
--
--
Mar 31, 2025
Pivotal Bioventure Partners Investment Advisor LLC
2.40M
5.78%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.79M
4.29%
+18.52K
+1.05%
Mar 31, 2025
abrdn Inc.
1.73M
4.15%
--
--
Mar 31, 2025
Almitas Capital LLC
1.30M
3.13%
+2.46K
+0.19%
Mar 31, 2025
The Vanguard Group, Inc.
971.93K
2.34%
+46.41K
+5.01%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
DFA Dimensional US Core Equity Market ETF
0%
ProShares Hedge Replication ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
Mehr Anzeigen
DFA Dimensional US Core Equity Market ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
iShares Micro-Cap ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
iShares Russell 2000 ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
Global X Russell 2000 Covered Call ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
